A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a study to understand if taking VTX2735 is safe and effective in participants
diagnosed with Cryopyrin-Associated Period Syndrome (CAPS). Approximately 10 patients will
take VTX2735 Dose A or VTX2735 Dose B.
The study consists of a screening/washout period of up to 28 weeks, a 2 week treatment
period, a treatment withdrawal period of up to 2 weeks, another 2 week treatment period, and
a 4 week follow up period. The maximum length of treatment is 4 weeks.